Keywords: Jazz Pharma, Meda, Women's health business, M&A

Jazz Pharma sells women's health business to Meda for $95 million

Article | 07 September 2012

US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced a definitive agreement to sell its women's health business, which includes six ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Meda

Jazz Pharmaceuticals

Go to company listing